27
Participants
Start Date
October 31, 2012
Primary Completion Date
December 31, 2014
Study Completion Date
December 31, 2014
Irosustat
Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
Mid Essex Hospital Services NHS Trust, Chelmsford
NHS Lothian, Edinburgh
NHS Greater Glasgow and Clyde, Glasgow
Royal Liverpool and Broadgreen University Hospital, Liverpool
Royal Free London, London
West Middlesex University Hospital NHS Trust, London
Imperial College Healthcare NHS Trust, London
University College London Hospitals NHS Foundation Trust, London
The Christie NHS Foundations Trust, Manchester
Collaborators (1)
Cancer Research UK
OTHER
Imperial College London
OTHER